文献速递儿科与产科急症呼吸衰竭与机械通气

利司扑兰治疗1型脊髓性肌萎缩症

Risdiplam in Type 1 Spinal Muscular Atrophy.
PubMed 文献 · N Engl J Med · 2021-02-24
一句话结论口服利司扑兰0.2 mg/kg/d可使1型SMA婴儿血SMN蛋白较基线升高1.9倍,7例高剂量组婴儿中7例独坐≥5秒(低剂量组无)。

本文为2-3期开放标签研究第1部分,纳入21例1-7月龄1型SMA婴儿(不能独坐),分低剂量组4例(12月最终剂量0.08 mg/kg/d)和高剂量组17例(0.2 mg/kg/d)。主要终点为安全性、药代/药效(含血SMN蛋白浓度)及第2部分剂量选择;探索性终点为独坐≥5秒能力。12月时血SMN蛋白中位数升高至基线3.0倍(低剂量)和1.9倍(高剂量)。严重不良事件含肺炎、呼吸道感染、急性呼吸衰竭,4例死于呼吸并发症;高剂量组7例、低剂量组0例可独坐≥5秒,最终选0.2 mg/kg/d进入第2部分。

要点

  • 研究纳入1-7月龄1型SMA婴儿(未达独坐),共21例,开放标签2-3期研究第1部分。
  • 12月最终剂量:低剂量组0.08 mg/kg/d(4例),高剂量组0.2 mg/kg/d(17例),口服给药。
  • 12月时血SMN蛋白中位数较低剂量组升3.0倍、高剂量组升1.9倍(基线中位数分别为1.31和2.54 ng/mL)。
  • 高剂量组7例、低剂量组0例可独坐≥5秒;研究选择0.2 mg/kg/d进入第2部分。
  • 严重不良事件包括肺炎、呼吸道感染、急性呼吸衰竭,4例死于呼吸并发症。

适用人群与场景

  • 1-7月龄的1型脊髓性肌萎缩症婴儿,特征为不能独坐。
  • 本研究为开放标签2-3期研究第1部分,未提及院前或ICU特定场景。

诊断标准与关键阈值

  • 1型脊髓性肌萎缩症的临床特征为婴儿不能达到独坐能力(原文描述)。
  • 原文未提及基因诊断或SMN蛋白水平的具体诊断界值。

处置流程与药物剂量

  • 口服利司扑兰,低剂量组12月最终剂量0.08 mg/kg/d,高剂量组0.2 mg/kg/d;研究选择0.2 mg/kg/d进入第2部分。
  • 原文未提及给药频次(除每日剂量外)、疗程、目标值或停药标准。
  • 原文未提及针对严重不良事件(肺炎、呼吸道感染、急性呼吸衰竭)的具体处理措施。

红旗征与不能漏的情况

  • 严重不良事件包括肺炎、呼吸道感染和急性呼吸衰竭,需警惕。
  • 截至发表时,4例婴儿死于呼吸并发症。

研究设计与关键结果

  • 研究类型:2-3期、两部分、开放标签研究第1部分;样本量21例婴儿;未提及中心数。
  • 干预:利司扑兰口服,低剂量组4例(12月最终剂量0.08 mg/kg/d),高剂量组17例(0.2 mg/kg/d)。
  • 主要终点:安全性、药代动力学、药效学(含血SMN蛋白浓度)及第2部分剂量选择。
  • 血SMN蛋白:基线中位数低剂量组1.31 ng/mL、高剂量组2.54 ng/mL;12月时分别升至3.05 ng/mL和5.66 ng/mL,为基线的3.0倍和1.9倍。
  • 探索性终点:高剂量组7例、低剂量组0例可独坐≥5秒。
  • 严重不良事件:肺炎、呼吸道感染、急性呼吸衰竭;4例死于呼吸并发症。
  • 最终选择0.2 mg/kg/d进入第2部分。

证据类型、等级与局限

  • 证据类型:2-3期开放标签研究(第1部分)。
  • 局限:开放标签、样本量小(21例)、无对照组、仅第1部分结果。

对床旁实践的改变

  • 对于1-7月龄1型SMA婴儿,口服利司扑兰0.2 mg/kg/d可升高血SMN蛋白并改善独坐能力(高剂量组7例可独坐≥5秒)。
  • 需警惕肺炎、呼吸道感染和急性呼吸衰竭等严重不良事件,4例死于呼吸并发症。
  • 本研究为开放标签小样本第1部分,结果需第2部分进一步验证;不适用于其他年龄或类型SMA患者。

指南或共识出处

  • 原文未提及指南或共识名称;研究由F. Hoffmann-La Roche资助,ClinicalTrials.gov编号NCT02913482。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Type 1 spinal muscular atrophy is a rare, progressive neuromuscular disease that is caused by low levels of functional survival of motor neuron (SMN) protein. Risdiplam is an orally administered, small molecule that modifies SMN2 pre-messenger RNA splicing and increases levels of functional SMN protein.

METHODS: We report the results of part 1 of a two-part, phase 2-3, open-label study of risdiplam in infants 1 to 7 months of age who had type 1 spinal muscular atrophy, which is characterized by the infant not attaining the ability to sit without support. Primary outcomes were safety, pharmacokinetics, pharmacodynamics (including the blood SMN protein concentration), and the selection of the risdiplam dose for part 2 of the study. Exploratory outcomes included the ability to sit without support for at least 5 seconds.

RESULTS: A total of 21 infants were enrolled. Four infants were in a low-dose cohort and were treated with a final dose at month 12 of 0.08 mg of risdiplam per kilogram of body weight per day, and 17 were in a high-dose cohort and were treated with a final dose at month 12 of 0.2 mg per kilogram per day. The baseline median SMN protein concentrations in blood were 1.31 ng per milliliter in the low-dose cohort and 2.54 ng per milliliter in the high-dose cohort; at 12 months, the median values increased to 3.05 ng per milliliter and 5.66 ng per milliliter, respectively, which represented a median of 3.0 times and 1.9 times the baseline values in the low-dose and high-dose cohorts, respectively. Serious adverse events included pneumonia, respiratory tract infection, and acute respiratory failure. At the time of this publication, 4 infants had died of respiratory complications. Seven infants in the high-dose cohort and no infants in the low-dose cohort were able to sit without support for at least 5 seconds. The higher dose of risdiplam (0.2 mg per kilogram per day) was selected for part 2 of the study.

CONCLUSIONS: In infants with type 1 spinal muscular atrophy, treatment with oral risdiplam led to an increased expression of functional SMN protein in the blood. (Funded by F. Hoffmann-La Roche; ClinicalTrials.gov number, NCT02913482.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Baranello G, Darras BT, Day JW, et al. Risdiplam in Type 1 Spinal Muscular Atrophy. N Engl J Med. 2021. PMID: 33626251. doi:10.1056/NEJMoa2009965

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。